<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Gene</td><td><italic>Erwinia</italic> ligand-gated ion channel (ELIC)</td><td>Synthetic gene from Genscript</td><td>UniProt <break/>P0C7B7</td><td/></tr><tr><td>Gene</td><td>Human 5-hydroxytryptamine receptor 3A (5-HT<sub>3A</sub> R)</td><td>John&#160;Peters laboratory&#160;(<xref ref-type="bibr" rid="bib4">Belelli et al., 1995</xref>)</td><td>GenBank NM_000869</td><td/></tr><tr><td>Cell line</td><td>C43 <italic>E. coli</italic> strain</td><td>Lucigen</td><td>#60446</td><td/></tr><tr><td>Cell line</td><td>WK6 <italic>E. coli</italic> strain</td><td><xref ref-type="bibr" rid="bib66">Zell and Fritz, 1987</xref> <break/></td><td/><td/></tr><tr><td>Cell line</td><td>TG1 <italic>E. coli</italic> strain</td><td>Lucigen</td><td>#60502</td><td/></tr><tr><td>Antibody</td><td>PAM-Nb</td><td/><td/><td>Nanobody obtained by immunizing an adult <italic>llama glama</italic> with recombinant ELIC protein. PAM-Nb was used at 1&#8211;30 &#956;M concentration in electrophysiology experiments. In protein crystals the PAM-Nb concentration is&#160;&gt;&#160;1 mM.</td></tr><tr><td>Antibody</td><td>NAM-Nb</td><td/><td/><td>Nanobody obtained by immunizing an adult <italic>llama glama</italic> with recombinant ELIC protein. NAM-Nb was used at 0.03&#8211;3 &#956;M concentration in electrophysiology experiments. In protein crystals the NAM-Nb concentration is&#160;&gt;&#160;1 mM.</td></tr><tr><td>Recombinant DNA reagent</td><td>pGEM-HE</td><td><xref ref-type="bibr" rid="bib36">Liman et al. (1992)</xref> <break/></td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>pMESy4</td><td/><td>GenBank KF415192</td><td/></tr><tr><td>Sequence-based reagent</td><td>P111C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;-<named-content content-type="sequence">caccaagttgtccatcTGcacggacagcatctgg</named-content>-3&#8217; <break/>5&#8217;-<named-content content-type="sequence">ccagatgctgtccgtgCAgatggacaacttggtg</named-content>- 3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>T112C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;-<named-content content-type="sequence">caagttgtccatccccTGCgacagcatctgggtcc</named-content>-3&#8217; <break/>5&#8217;-<named-content content-type="sequence">ggacccagatgctgtcGCAggggatggacaacttg</named-content>-3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>N147C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;-<named-content content-type="sequence">caaggcgaagttcagTGctacaagccccttcagg</named-content>-3&#8217; <break/>5&#8217;-<named-content content-type="sequence">cctgaaggggcttgtagCActgaacttcgccttg</named-content>-3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>K149C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;-<named-content content-type="sequence">ggcgaagttcagaactacTGCccccttcaggtggtga</named-content>-3&#8217; <break/>5&#8217;- <named-content content-type="sequence">tcaccacctgaaggggGCAgtagttctgaacttcgcc</named-content>-3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>L151C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;- <named-content content-type="sequence">gttcagaactacaagcccTGtcaggtggtgactgc</named-content>-3&#8217; <break/>5&#8217;-<named-content content-type="sequence">gcagtcaccacctgaCAgggcttgtagttctgaac</named-content>-3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>Y86C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;- <named-content content-type="sequence">ctggtaccggcagtGctggactgatgag</named-content>-3&#8217; <break/>5&#8217;-<named-content content-type="sequence">ctcatcagtccagCactgccggtaccag</named-content>-3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>F125C oligonucleotide forward and reverse</td><td/><td/><td>5&#8217;-<named-content content-type="sequence">ggacattctcatcaatgagtGcgtggatgtggg</named-content>-3&#8217; <break/>5&#8217;-<named-content content-type="sequence">cccacatccacgCactcattgatgagaatgtcc</named-content>-3&#8217;</td></tr><tr><td>Sequence-based reagent</td><td>Primer for nanobody library generation <break/>CALL001</td><td><xref ref-type="bibr" rid="bib49">Pardon et al. (2014)</xref> <break/></td><td/><td>5&#8242;-<named-content content-type="sequence">GTCCTGGCTGCTCTTCTACAAGG</named-content>-3&#8242;</td></tr><tr><td>Sequence-based reagent</td><td>Primer for nanobody library generation <break/>CALL002</td><td><xref ref-type="bibr" rid="bib49">Pardon et al. (2014)</xref> <break/></td><td/><td>5&#8242;-<named-content content-type="sequence">GGT ACGTGCTGTTGAACTGTTCC</named-content>-3&#8242;</td></tr><tr><td>Sequence-based reagent</td><td>Primer for nanobody library generation <break/>VHH-Back</td><td><xref ref-type="bibr" rid="bib49">Pardon et al. (2014)</xref> <break/></td><td/><td>5&#8242;-<named-content content-type="sequence">GATGTGCAGCTGCAG GAGTCTGGRGGAGG</named-content>-3&#8242;(PstI)</td></tr><tr><td>Sequence-based reagent</td><td>Primer for nanobody library generation <break/>VHH-For</td><td><xref ref-type="bibr" rid="bib49">Pardon et al. (2014)</xref> <break/></td><td/><td>5&#8242;-<named-content content-type="sequence">CTAGTGCGGCCGCTGG AGACGGTGACCTGGGT</named-content>-3&#8242;(Eco91I)</td></tr><tr><td>Sequence-based reagent</td><td>Primer for nanobody library analysis <break/>MP57</td><td><xref ref-type="bibr" rid="bib49">Pardon et al. (2014)</xref> <break/></td><td/><td>5&#8242;-<named-content content-type="sequence">TTATGCTTCCGGCTC GTATG-</named-content>3&#8242;</td></tr><tr><td>Peptide, recombinant protein</td><td>Primer for nanobody library analysis <break/>GIII</td><td><xref ref-type="bibr" rid="bib49">Pardon et al. (2014)</xref> <break/></td><td/><td>5&#8242;-<named-content content-type="sequence">CCACAGACAGCCCTCATAG</named-content>-3&#8242;</td></tr><tr><td>Commercial assay or kit</td><td>mMessage mMachine T7 Transcription kit</td><td>ThermoFisher Scientific</td><td>#AM1344</td><td/></tr><tr><td>Commercial assay or kit</td><td>Ni Sepharose 6 Fast Flow resin</td><td>GE Healthcare</td><td>#17531802</td><td/></tr><tr><td>Commercial assay or kit</td><td>Superdex 75 10/300 GL column</td><td>GE Healthcare</td><td># 17-5174-01</td><td/></tr><tr><td>Commercial assay or kit</td><td>Superdex 200 Increase 10/300 GL</td><td>GE Healthcare</td><td># 28990944</td><td/></tr><tr><td>Commercial assay or kit</td><td>QuikChange Site-Directed Mutagenesis Kit</td><td>Agilent</td><td># 200518</td><td/></tr><tr><td>Chemical compound, drug</td><td>5-HT creatinine sulphate</td><td>Sigma-Aldrich</td><td>#S2805</td><td/></tr><tr><td>Chemical compound, drug</td><td>MTSEA-biotin</td><td>Biotium</td><td>#90064</td><td/></tr><tr><td>Chemical compound, drug</td><td>GABA</td><td>Sigma-Aldrich</td><td>#A2129</td><td/></tr><tr><td>Chemical compound, drug</td><td><italic>E. coli</italic> total lipid extract</td><td>Avanti Polar Lipids</td><td>#100500P</td><td/></tr><tr><td>Chemical compound, drug</td><td>Anagrade n-undecyl-&#946;-D-maltoside (UDM)</td><td>Anatrace</td><td>#U300</td><td/></tr><tr><td>Software, algorithm</td><td>GraphPad Prism Software v4.03</td><td/><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>CCP4</td><td><xref ref-type="bibr" rid="bib65">Winn et al., 2011</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>STARANISO</td><td><xref ref-type="bibr" rid="bib61">Tickle et al., 2018</xref> <ext-link ext-link-type="uri" xlink:href="http://staraniso.globalphasing.org">http://staraniso.globalphasing.org</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>XDS</td><td><xref ref-type="bibr" rid="bib29">Kabsch, 2010</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Coot</td><td><xref ref-type="bibr" rid="bib15">Emsley et al. (2010)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Buster</td><td><xref ref-type="bibr" rid="bib57">Smart et al. (2012)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>PDB-REDO</td><td><xref ref-type="bibr" rid="bib27">Joosten et al. (2014)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>MolProbity</td><td><xref ref-type="bibr" rid="bib10">Chen et al. (2010)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>PyMOL v2.3.0</td><td>Schr&#246;dinger</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_000305">SCR_000305</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>HOLE</td><td><xref ref-type="bibr" rid="bib56">Smart et al. (1996)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>CAVER</td><td><xref ref-type="bibr" rid="bib28">Jurcik et al. (2018)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>PHENIX</td><td><xref ref-type="bibr" rid="bib1">Adams et al. (2010)</xref> <break/></td><td/><td/></tr><tr><td>Software, algorithm</td><td>HiClamp</td><td>Multi Channel Systems</td><td/><td/></tr></tbody></table></table-wrap>